---
title: "Impact BioMedical Inc. (IBO.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/IBO.US.md"
symbol: "IBO.US"
name: "Impact BioMedical Inc."
industry: "制药"
---

# Impact BioMedical Inc. (IBO.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.impactbiomedinc.com](https://www.impactbiomedinc.com) |

## Company Profile

Impact BioMedical Inc. 发现、开发并商业化产品和技术，以满足美国人类医疗保健和健康领域的未满足需求，专注于特种生物制药、抗病毒药物、抗微生物药物、消费者医疗保健和健康产品。该公司提供 Linebacker，这是一个小分子电亲和增强多酚化合物的平台，应用于肿瘤学、炎症性疾病和神经学；以及 Laetose 技术，该技术源自糖和肌醇的独特组合，可以抑制单独糖的炎症和代谢反应。它还开发了功能性香氛配方，这是一套包含特殊植物成分的功能性香氛，应用于抗微生物，并作为驱虫剂、洗涤剂、乳液、洗发水、织物和其他物质的添加剂

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-28T04:30:15.000Z

**Overall: E (0.81)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 185 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% |  |
| Net Profit YoY | -3893.22% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | -3.84 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 45.54M |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 25000.00 |  |


**Multi Score**: E

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -455.13% | E |
| Profit Margin | -176764.00% | E |
| Gross Margin | 94.44% | A |

#### Growth Score: D

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 0.00% | D |
| Net Profit YoY | -3893.22% | E |
| Total Assets YoY | -61.01% | E |
| Net Assets YoY | -125.77% | E |

#### Cash Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -0.06% | D |
| OCF YoY | 0.00% | C |

#### Operating Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 0.00 | E |

#### Debt Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 148.62% | E |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Impact BioMedical Inc.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-455.13%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-176764.00%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "94.44%",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "D",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "0.00%",
          "rating": "D"
        },
        {
          "name": "Net Profit YoY",
          "value": "-3893.22%",
          "rating": "E"
        },
        {
          "name": "Total Assets YoY",
          "value": "-61.01%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-125.77%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "C",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-0.06%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "0.00%",
          "rating": "C"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "E",
      "indicators": [
        {
          "name": "Turnover",
          "value": "0.00",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "E",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "148.62%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | 礼来 (US.LLY) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (US.RHHVF) | A | B | B | D | C | B |
| 03 | 罗氏(ADR) (US.RHHBY) | A | B | B | D | C | B |
| 04 | 阿斯利康 (US.AZN) | A | B | C | D | C | B |
| 05 | 诺华制药 (US.NVS) | A | B | C | D | C | B |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -1.03 | 100/257 | 21.72 | 11.95 | 6.56 |
| PB | -3.84 | 210/257 | 2.07 | 1.63 | 1.21 |
| PS (TTM) | 1821.66 | 154/257 | 2034.67 | 1837.57 | 1042.55 |
| Dividend Yield | 0.00% | - | - | - | - |

## References

- [Company Overview](https://longbridge.com/en/quote/IBO.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/IBO.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/IBO.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.